98%
921
2 minutes
20
Introduction: Premix insulin is the most commonly used insulin preparation in India. The first Indian premix guidelines were developed in 2009 and thereafter were updated in 2013. There is a need to revisit the Indian premix insulin guidelines, in view of emerging evidence and introduction of newer co-formulations.
Objective: The present consensus has been developed to evaluate available premix formulations, examine existing evidence related to premix formulations, and evolve consensus statement of recommendations on the topic.
Methods: A meeting of experts from across India was conducted at Chennai in July 2016. The expert committee evaluated each premix insulin regimen with reference to 1) Current recommendations by various guidelines, 2) Approved pack inserts and 3) Published scientific literature. The information was debated and discussed within the expert group committee, to arrive at seven consensus-based recommendations for initiation and intensification with premix insulin.
Results: Recommendations based on consensus on initiation and intensification of premix insulin in type 2 diabetes mellitus (T2DM) management were developed for the following situations. 1) Initiation of premix insulin co-formulation at diagnosis, 2) Initiation of once daily (OD) premix insulin/co-formulation, 3) Initiation of twice daily (BID) premix insulin/co-formulation 4) Intensification with BID and thrice daily (TID) premix insulin/co-formulation. Three recommendations pertained to the use of premix insulin in other forms of diabetes, or in specific situations: 5) Use of premix insulin in gestational diabetes mellitus 6) Use of premix insulin in type 1 Diabetes Mellitus (T1DM) 7) Premix insulin use during Ramadan.
Conclusions: In the setting of high carbohydrate consumption in India, or in patients with predominant post prandial hyperglycemia, premix insulin/co-formulation can offer effective and convenient glycemic control. This paper will help healthcare practitioners initiate and intensify premix insulin effectively.
Download full-text PDF |
Source |
---|
Prim Care Diabetes
August 2025
Department of Endocrinology, Singapore General Hospital, 20 College Road, 169856, Singapore. Electronic address:
Aims: Identifying non-glycemic factors associated with high Glucose variability (GV).
Methods: A cross-sectional observational study recruited people with type 2 diabetes, who wore a Freestyle Libre Pro CGM.
Independent Variables: Age, sex, BMI, diabetes medication, diabetes duration, HbA1c and estimated glomerular filtration rate (eGFR).
Diabetes Ther
August 2025
Novo Nordisk Service Centre India Private Ltd, Plot Number 149-A, Mindcomp Tech Park, 4th Floor, 2nd Phase, EPIP Area, Whitefield, Bangalore, India.
Introduction: Although many people with diabetes are treated with insulin in Japan, data on the incidence of hypoglycemia in this population are limited. This real-world, retrospective, cohort analysis assessed the incidence of hypoglycemia-related hospitalization, and the time to first hypoglycemia-related hospitalization, after insulin initiation in adults with type 2 diabetes (T2D) in Japan.
Methods: Adults with T2D who initiated basal, basal-bolus, or premix insulin between January 2016 and September 2022 were identified from the Medical Data Vision (MDV) database.
Diabetol Metab Syndr
August 2025
Department of Endocrinology and Metabolism, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Darülaceze Street, Sisli, 34384, Istanbul, Türkiye.
Aims: This study aimed to evaluate the clinical outcomes of switching from disposable insulin delivery pens to reusable insulin pens with a penfill cartridge system for the co-formulation of insulin degludec and insulin aspart (IDegAsp) in patients with type 2 diabetes (T2D) in Türkiye. We assessed the impact on glycemic control to evaluate the sustainability of this transition.
Methods: A total of 226 adults with T2D who were initiating or switching to IDegAsp reusable cartridge insulin pens at a tertiary center in Türkiye were followed for 6 months.
Diabetes Spectr
February 2025
Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY.
Objective: The purpose of this study was to evaluate insulin dose requirements after the addition of the dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist tirzepatide compared with the GLP-1 receptor agonists injectable semaglutide and dulaglutide in people with type 2 diabetes.
Research Design And Methods: This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin therapy (basal with or without bolus or premixed insulin).
Results: A total of 135 patients were included in the study.
Curr Ther Res Clin Exp
June 2025
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Background: Glucagon leads to substantial but short-lived subcutaneous vasodilation. Using micro-amounts of glucagon at the insulin injection site increases insulin absorption.
Objective: We hypothesized that a premixed solution of insulin and nanogram doses of glucagon would improve the pharmacokinetic and pharmacodynamic properties of subcutaneously injected insulin.